Review of the pharmacokinetics, interactions and adverse reactions of cyclosporine in people, dogs and cats

Veterinary Record

Volumn 152, Issue 24, 2003, Pages 739-748

  Robson, D ^a  

^a Melbourne Veterinary Referral Centre   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMINOGLYCOSIDE DERIVATIVE; AMLODIPINE; AMPHOTERICIN B; ATOPICA; CIMETIDINE; CIPROFLOXACIN; COLCHICINE; COTRIMOXAZOLE; CYCLOSPORIN A; DIGOXIN; DILTIAZEM; DOXYCYCLINE; ERYTHROMYCIN; ITRACONAZOLE; IVERMECTIN; KETOCONAZOLE; MELPHALAN; METHYLPREDNISOLONE; METOCLOPRAMIDE; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PHENOBARBITAL; PREDNISONE; RANITIDINE; RECOMBINANT ERYTHROPOIETIN; RIFAMPICIN; TERBINAFINE; UNINDEXED DRUG; VERAPAMIL;

ACUTE PANCREATITIS; ADULT RESPIRATORY DISTRESS SYNDROME; AMENORRHEA; ANEMIA; BRAIN DISEASE; CAT; CHOLELITHIASIS; CONSCIOUSNESS DISORDER; CONVULSION; DEPRESSION; DOG; DRUG ADMINISTRATION ROUTE; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG COST; DRUG CROSS REACTIVITY; DRUG DOSE REDUCTION; DRUG FORMULATION; DRUG METABOLISM; DRUG PENETRATION; DRUG USE; DYSMENORRHEA; EDEMA; FATIGUE; FOLLICULITIS; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; HEADACHE; HEARING LOSS; HIRSUTISM; HUMAN; HYPERAMYLASEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICEMIA; HYPOMAGNESEMIA; LETHARGY; LEUKOPENIA; LYMPHOPROLIFERATIVE DISEASE; MICROEMULSION; MOTOR DYSFUNCTION; MOUSE; MUSCLE CRAMP; MYOPATHY; NEPHROTOXICITY; NONHUMAN; PIGMENT DISORDER; PRURITUS; RASH; RAT; REVIEW; SINUSITIS; SKIN DISEASE; SKIN PENETRATION; STRATUM CORNEUM; THROMBOCYTOPENIA; TINNITUS; TREMOR; VETERINARY MEDICINE; VISUAL DISORDER; VISUAL HALLUCINATION;

CANIS FAMILIARIS; FELIS CATUS;

EID: 0038112049     PISSN: 00424900     EISSN: None     Source Type: Journal    
DOI: 10.1136/vr.152.24.739     Document Type: Review

References (92)

1. ABBAS, A. K., LICHTMAN, A. H.&POBER, J. S. (1997) Cellular and Molecular Immunology. 3rd edn. Philadelphia, W. B. Saunders. pp 166, 299-301
2. AICHER, L., WAHL, D., ARCE, A., GRENET, O.&STEINER, S. (1998) New insights into cyclosporine A nephrotoxicity by proteome analysis. Electophoresis 19, 1998-2003
3. AKDIS, C. A., BLESKEN, T., AKDIS, M., WUTHRICH, B.&BLASER, K. (1998) Role of interleukin 10 in specific immunotherapy. Journal of Clinical Investigation 102, 98-106
4. ALBENGRES, E.&TILLEMENT, J. P. (1992) Cyclosporin and ketoconazole drug interaction or therapeutic association? International Journal of Clinical Pharmacology, Therapy and Toxicology 30, 555-570
5. AZANA, J. M., DE MISA, R. F., BOIXEDA, J. P.&LEDO, A. (1993) Topical cyclosporine for cicatrichial pemphigoid. Journal of the American Academy of Dermatology 28, 134-135
6. BELLINGHAUSEN, I., KNOP, J.&SALOGA, J. (2001) The role of interleukin 10 in the regulation of allergic immune responses. International Archives of Allergy and Immunology 126, 97-101
7. BENNETT, W. M. (1997) Cyclosporine nephrotoxicity: implications for dermatology. International Journal of Dermatology 36 (Suppl 1), 11-14
8. BERNSTEEN, L., GREGORY, C. R., ARONSON, L. R., LIRTZMAN, R. A.&BRUMMER, D. G. (1999) Acute toxoplasmosis following renal transplantation in three cats and a dog. Journal of the American Veterinary Medical Association 215, 1123-1126
9. BERTH-JONES, J., GRAHAM-BROWN, R. A., MARKS, R., CAMP, R. D. R., ENGLISH, J. S. C., FREEMAN, K., HOLDEN, C. A., ROGERS, S. C. F., OLIWIEKI, S., FRIEDMANN, P. S., LEWIS-JONES, M. S., ARCHER, C. B., ADRIAANS, B., DOUGLAS, W. S.&ALLEN, B. R. (1997) Long term efficacy and safety of cyclosporine in severe adult atopic dermatitis. British Journal of Dermatology 136, 76-81
10. BURTON, G. G., ROBSON, D. C., BASSETT, R. J.&KIERMIER, A. (2002) A pilot trial on the effect of cyclosporine on intradermal-skin testing in dogs with atopic dermatitis. In Proceedings of the 17th Annual Members Meeting of the American Academy of Veterinary Dermatology and the American College of Veterinary Dermatology. p 20
11. CAMP, R. D. R., REITAMO, S., FRIEDMANN, P. S., HO, V. & HEULE, F. (1993) Cyclosporin A in severe, therapy-resistant atopic dermatitis: report of an international workshop. British Journal of Dermatology 129, 217-220
12. CAROTHERS, M. A, KWOCHKA, K. W.&ROJKO, J. L. (1991) Cyclosporine-responsive granulomatous sebaceous adenitis in a dog. Journal of the American Veterinary Medical Association 198, 1645-1648
13. CARRIER, M., TRONC, F., STEWART, D.&PELLETIER, L. C. (1991) Dose-dependent effect of cyclosporin on renal arterial resistance in dogs. American Journal of Physiology 261, H1791-H1796
14. CASWELL, A. (1999) E-MIMs 4.0 St Leonards, MIMS Australia
15. CATHER, J. C., ABRAMOVITS, W.&MENTER, A. (2001) Cyclosporin and tacrolimus in dermatology. Dermatologic Clinics 19, 119-137
16. CHEN, S. S., LI, Q., PEARLMAN, E.&CHEN, W. H. (1992) Dual mechanisms of potentiation of murine antigen-specific IgE production by cyclosporin A in vitro. Journal of Immunology 149, 762-767
17. CHOI, H. K., FLYNN, G. L.&AMIDON, G. L. (1995) Percutaneous absorption and dermal delivery of cyclosporin A. Journal of Pharmaceutical Sciences 84, 581-583
18. CIRESI, D. L., LLOYD, M. A., SANDBERG, S. M., HEUBLEIN, D. M. &EDWARDS, B. S. (1992) The sodium retaining effects of cyclosporine. Kidney International 41, 1599-1605
19. CIRILLO, R., TRIGGIANI, M., SIRI, L., CICCARELLI, A., PETTIT, G. R., CONDORELLI, M.&MARONE, G. (1990) Cyclosporin A rapidly inhibits mediator release from human basophils presumably by interacting with cyclophilin. Journal of Immunology 144, 3891-3897
20. COLE, G. W., SHIMOMAYE, S.&GOODMAN, M. (1988) The effect of topical cyclosporin A on the elicitation phase of allergic contact dermatitis. Contact Dermatitis 19, 129-132
21. DAHLINGER J., GREGORY, C.&BEA, J. (1998) Effect of ketoconazole on cyclosporine dose in healthy dogs. Veterinary Surgery 27, 64-68
22. DAIGLE, J.C., HOSGOOD, G., FOIL, C.S.&HUNTER, R.P. (2001) The effect of cimetidine on the pharmacokinetics of orally administered cyclosporin in healthy dogs. American Journal of Veterinary Research 62, 1046-1050
23. DRESSER, G.K, SPENCE, J.D.&BAILEY, D.G. (2000) Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clinical Pharmacokinetics 38, 41-57
24. DUNCAN, J.I. (1994) Differential inhitibion of cutaneous T-cell mediated reactions and epidermal cell proliferation by cyclosporin A, FK-506, and rapamycin. Journal of Investigative Dermatology 102, 84-88
25. DUNCAN, J.I., PAYNE, S.N., WINFIELD, A.J., ORMEROD, A.D. & THOMPSON, A.W. (1990) Enhanced percutaneous absorption of a novel topical cyclosporin A formula and assessment of its immunosuppresive activity. British Journal of Dermatology 123, 631-640
26. DUNCAN, J.I., WAKEEL, R.A., WINFIELD, A.J., ORMEROD, A.D. & THOMPSON A.W. (1993) Immunomodulation of psoriasis with a topical cyclosporin A formulation. Acta Dermato-Venereologica 73, 84-87
27. EAGLING, V.A. PROFIT, L.&BACK, D.J. (1999) Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. British Journal of Clinical Pharmacology 48, 543-552
28. EDWARDS, D.J., FITZSIMMONS, M.E., SCHUETZ, E.G., YASUDA, K., DUCHARME, M.P., WARBASSE, L.H., WOSTER, P.M., SCHUETZ, J.D.&WATKINS, P. (1999) 6′,7′-Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein. Clinical Pharmacology and Therapeutics 65, 237-244
29. EISEN, D.&ELLIS, C.N. (1990) Topical cyclosporine for oral mucosal disorders. Journal of the American Academy of Dermatology 23, 1259-1264
30. FARRELL, A.M., ANTROBUS, P., SIMPSON, D., POWELL, S., CHAPEL H.M.&FERRY, B.L. (2001) A rapid flow cytometric assay to detect CD4+ and CD8+ T-helper (Th) 0, Th1 and Th2 cells in whole blood and its application to study cytokine levels in atopic dermatitis before and after cyclosporin therapy. British Journal of Dermatology 144, 24-33
31. FONTAINE, J.&OLIVRY, T. (2001) Treatment of canine atopic dermatitis with cyclosporine: a pilot clinical study. Veterinary Record 148, 662-663
32. FUGH-BERMAN, A. (2000) Herb-drug interactions. Lancet 355, 134-138 (Published erratum (2000) Lancet 355, 1020)
33. GARCIA, G., FERRER, L. DEMORA, F.&PUIGDEMONT, A. (1998) Inhibition of histamine release from dispersed canine mast cells by cyclosporin A, rolipram and salbutamol, but not by dexamethasone or sodium cromoglycate. Veterinary Dermatology 9, 81-86
34. GILGER, B.C., ANDREWS, J.A., WILKIE, D.A. WYMAN, M & LAIRMORE, M. (1995) Cellular immunity in dogs with keratoconjunctivitis sicca before and efter treatment with 2% cyclosporin. Veterinary Immunology and Immunopathology 49, 199-208
35. GREGORY, C.R., MADEWELL, B.R., GRIFFEY, S.M.&TORTEN, M. (1991) Feline leukaemia virus-associated lymphosarcoma following retal transplantation in a car. Transplant 52, 1097-1099
36. GRIFFITHS, L.G., SULLIVAN, M.&BORLAND, W.W. (1999) Cyclosporin as the sole treatment for anal furunculosis: preliminary results. Journal of Small Animal Practice 40, 569-572
37. GUO, J., PING, Q., SUN, G.&JIAO, C. (2000) Lecithin vesicular carriers for transdermal delivery of cyclosporin A. International Journal of Pharmacology 194, 201-207
38. HAIG, D.M., HUTCHISON, G.&HUGH, W.R. (1998) The effect of cyclosporin A on acquired immunity to orf virus infection: inhibition of CD8+ T-cell recruitment and activation. In advances in Veterinary Dermatology 3, Eds K.W. Kwochka, T. Willemse, C. von Tscharrer. Oxford, Butterworth Heinemann. pp 95-102.
39. HERMANN, R.C., TAYLOR, R.S., ELLIS, C.N., WILLIAMS, N.A., WEINER N.D. FLYNN, G.L., ANNESLEY, T.M.&VOORHEES, J.J. (1988) Topical ciclosporine for psoriasis: in vitro skin penetration and clinical study. Skin Pharmacology 1, 246-249
40. JACOB, L.P., MALHOTRA, D., CHAN, L.&SHAPIRO, J.I. (1999) Absence of a dose-response of cyclosporine levels to clinically used doses of diltiazem and verapamil. American Journal of Kidney Disease 33, 301-303
41. JITSUKAWA, K., RING, J., WEYER, U., KIMMIG, W.&RADLOFF, H. (1992) Topical cyclosporine in chronic benign familial pemiphigus (Hailey-Hailey disease). Journal of the American Academy of Dermatology 27, 625-626
42. KRUPP, P.&MONKA, C. (1990) Side-effect profile of cyclosporin in patients treated for psoriasis. British Journal of Dermatology 122 (Suppl), 46-56
43. KU, Y.M., MIN, D.I.&FLANIGAN, M. (1998) Effects of grapefruit juice on the pharmacokinetics of microemulsion cyclosporine and its metabolite in healthy volunteers: does the formulation difference matter? Journal of Clinical Pharmacology 38, 959-965
44. KYLES, A.E., GREGORY, C.R., WOOLDRIGE, J.D., MATHEWS, K.G., ARONSON, L.R., BERNSTEEN, L.&ILKIW, J.E. (1999) Management of hypertension controls postoperative neurologic disorders after renal transplantation in cats. Veterinary Surgery 28, 436-441
45. LEBWOHL, M., ELLIS, C. GOTTLIEB, A., KOO, J., KRUEGER, G., LINDEN, K., SHUPACK, J.&WEINSTEIN G. (1998) Cyclosporine consensus conference: with emphasis on the treatment of psoriasis. Journal of the American Academy of Dermatology 39, 464-475
46. LIM K.K., SU, W.P., SCHROETER, A.L., SABERS, C.J., ABRAHAM, R.T.&PITTELKOW, M.R. (1996) Cyclosporine in the treatment of dermatologic disease: an update. Mayo Clinic Proceedings 71, 1182-1191
47. LO, A.C.Y., LUI, S.L., LO, W.K., CHAN, D.T.M.&CHENG, I.K.P. (1997) The interaction of terbinafine and cyclosporine A in renal transplant patients. British Journal of Clinical Pharmacology 43, 340-341
48. LOWN, K.S., MAYO, R.R., LEICHTMAN, A.B., HSAIO, H.L., TURGEON, D.K., SCHMIEDLIN-REN, P., BROWN, M.B., GUO, W., ROSSI, S.J., BENET, L.Z.&WATKINS, P.B. (1997) Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clinical Pharmacology and Therapeutics 62, 248-260
49. MCANULTY, J.F.&LENSMEYER, G.L. (1999) The effects of ketoconazole on the pharmacokinetics of cyclosporine A in cats. Veterinary Surgery 28, 448-455
50. MARQUESSANTOS, L.F., BERNARDO, R.R., PAULA, E.F.D. & RUMJANEK, V.M. (1999) Cyclosporin A and trifluoperazine, two resistance-modulating agents, increase ivermectin neurotoxicity in mice. Pharmacolgoy and Toxicology 84, 125-129
51. Martin, J.E., DAOUD, A.J., SCHROEDER, T.J.&FIRST, M.R. (1999) The clinical and economic potential of cyclosporin drug interactions. Pharmacoeconomics 15, 317-337
52. MATHEWS, K.A.&SUKHIANI, H.R. (1997) Randomised controlled trial of cyclosporine for treatment of perianal fistulas in dogs. Journal of the American Veterinary Medical Association 211, 1249-1253
53. MOUATT, J.G. (2002) Cyclosporin and ketoconazole interaction for treatment of perianal fistulas in the dog. Australian Veterinary Journal 80, 207-211
54. MUNRO, C.S., HIGGINS, E.M., MARKS, J.M., DALY, B.M., FRIEDMANN, P.S.&SHUSTER, S. (1991) Cyclosporin A in atopic dermatitis: therapeutic response is dissociated from effects of allergic reactions. British Journal of Dermatology 124, 43-48
55. MYRE, S.A., SCHOEDER, T.J., GRUND, V.R., WANDSTRAT, T.L., NICELY, P.G., PESCE, A.J.&FIRST, M.R. (1991) Critical ketoconazole dosage range for ciclosporin clearance inhibition in the dog. Pharmacology 43, 233-241
56. NAEYAERT,J.M., LACHAPELLE, J.M., DEGREEF, H., DE LA BRASSINNE,M., HEENEN, M.&LAMBERT, J. (1999) Cyclosporin in atopic dermatitis: review of the literature and outline of a Belgian consensus. Dermatology 198, 145-152
57. NAKASHIMA. M., ZHAO, M.F., OHYA, H., SAKURAI, M., SASAKI, H., MATSUYAMA, K.&ICHIKAWA, M. (1996) Evaluation of in-vitro transdermal absorption of cyclosporin with absorption enhancer using intradermal microdialysis in rats. Journal of Pharmacy and Pharmacology 48, 1143-1146
58. OLIVRY, T., POWER, H.T., WOO, J.C., MOORE, P.F.&TOBIN, D.J. (2000) Anti-isthmus autoimmunity in a novel feline acquired alopecia resembling pseudopelade of humans. Veterinary Dermatology 11, 261-270
59. OLIVRY, T., RIVIERRE, C., JACKSON, H.A., MURPHY, K.M., DAVIDSON, G.&SOUSA, C.A. (2002) Cyclosporin-A decrease skin lesions and pruritus in dogs with atopic dermatitis: a prednisolone-controlled blinded trial (Abstract). Veterinary Dermatologist 13, 77-87
60. OMAR. G., WHITING, P.H., HAWKSWORTH, G.M., HUMPHREY, M.H. & BURKE, M.D. (1997) Ketoconazole and fluconazole inhibition of the metabolism of cyclosporin A by human liver in vitro. Therapeutic Drug Monitoring 19, 436-445
61. PAPICH, M.G. (1998) Immunosuppressive Drug Therapy. In Proceedings of the 14th Annual Members Meeting of the American Academy of Veterinary Dermatology and American College of Veterinary Dermatology; Concurrent Session Notes. pp 41-48
62. PRUD'HOMME, G.J.&VANIER, L.E. (1993) Cyclosporine, tolerance, and autoimmunity. Clinical Immunology and Immunopathology 66, 185-192
63. RAFIQ, K., CHARITIDOU, L., BULLENS, D.M., KASRAN, A., LORRE, K., CEUPPENS, J.&VAN GOOL, S.W. (2001) Regulation of the IL-10 production by human T cells. Scandinavian Journal of Immunology 53, 139-147
64. READ, R.A. (1996) Cyclosporin and its treatment of opthalmic disease in animals. Australian Veterinary Practioners 26, 86-91
65. REEDY, L.M., MILLER, W.H.&WILLEMSE, T. (1997) Allergic Skin Diseases of Dogs and Cats. 2nd edn. Philadelphia, W.B. Saunders. pp 118-119
66. REYNOLDS, J.E.F. (1993) Martindale's Extra Pharmacopeia. 30th edn. London, Pharmaceutical Press. p467
67. ROSEBAUM, M. (1999) Cyclosporine. Derm Dialgue. Newsletter of the American Academy of Veterinary Dermatology/American College of Veterinary Dermatology, Summer 1999. pp 5-7
68. ROSENKRANTZ, W.S. GRIFFIN, C.E.&BARR, R.J. (1999) Clinical evaluation of cyclosporine in animal models with cutaneous immune-mediated disease and epitheliotropic lymphoma. Journal of the American Animal Hospital Association 250, 377-384
69. RYFFEL, B. (1982) Experimental toxicological studies with cyclosproin A. In Cyclosporin A. Ed D.J.G. White. Amsterdam, Elsevier Biomedical Press. pp 45-75
70. SCHMOOK, F.P., STUTZ, A.&REINHARDT, J. (1993) Penetration of Sandimmune (cyclosporine A) in rat skin in vitro. Effects of penetration enhancers and solvents. Skinm Pharmacology 6, 116-124
71. SCOTT, D.W., MILLER, R.&GRIFFIN, C.E. (2001) Dermatology therapy. In Kirk's Small Animal Dermatology. 6th edn. Philadelphia, W.B. Saunders. pp 243-244, 508
72. SEIBEL, W., SUNDBERG, J.P., LESKO, L.J., SAUK, J.J., MCCLEARY, L.B.&HASSELL, T.M. (1989a) Cutaneous papillomatous hyperplasia in cyclosporine-A-treated beagles. Journal of Investigative Dermatology 93, 224-230
73. SEIBEL, W., YAHIA, N.A. MCCLEARY, L.B., LESKO, L.H. & HASSELL, T.M. (1989b) Cyclosporine-induced gingival overgrowth in beagle dogs. Journal of Oral Phathology and Medicine 18, 240-245
74. SLOAN-LANCASTER, J., EVAVOLD, B.D.&ALLEN, P.M. (1994) Th2 cell clonal anergy as a consequence of partial activation. Journal of Experimental Medicine 180, 1195-1205
75. SMITH, S.G. (1996) Neoral (cyclosporin) in dermatology: technical aspects. British Journal of Dermatology 135 (Suppl 48), 2-4
76. STEFFAN, J., STREHLAU, M., MAURER, M.&ROHLFS, A. (2001) Cyclosporine A population kinetics in dogs. In Proceedings of the 17th Annual Congress of the European Society of Veterinary Dermatology/European College of Veterinary Dermatology. p 179
77. Su, Q., WEBER, L., LE HIR, M. ZENKE, G.&RYFFEL, B. (1995) Nephrotoxicity of cyclosporin A and FK506: inhibition of calcineurin phosphatase. Renal Physiology and Biochemistry 18, 128-139
78. SURBER, C., ITIN, P.&BUCHNER, S. (1992a) Clinical controversy on the effect of topical ciclosporin: what is the target site? Dermatology 185, 242-245
79. SURBER, C., ITIN, P., BUCHNER, S.&MAIBACH, H.I. (1992b) Effect of a new topical cyclosporin formulation on human allergic contact dermatitis. Contact Dermatitis 26, 116-119
80. SZABO, G., GAVALA, C.&MANDREKAR, P. (2001) Tacrolimus and cyclosporin A inhibit allostimulatory capacity and cytokine production of human myeloid dendritic cells. Journal of Investigative Medicine 49, 442-449
81. TRAN, H.S., MALLI, D., CHRZANOWSKI, F.A., PUC, M.M., MATTHEWS M.S.&HEWITT, C.W. (1999) Site-specific immunosuppression using a new formulation of topical cyclosporine A with polyethylene glycol-8 glyceryl caprylate/caprate. Journal of Surgical Research 83, 136-140
82. VADEN, S.L. (1995) Cyclosporin. In Current Veterinary Therapy XXII. Eds R. W. Kirk, J.D. Bonagura. Philadelphia, W.B. Saunders. pp 73-77
83. VADEN, S.L. (1997) Cyclosporin and tacrolimus. Seminars in Veterinary Medicine and Surgery (Small Animal) 12, 161-166
84. VALDIMARSSON, H. (1990) Immunity during cyclosporine therapy. Journal of the American Academy of Dermatology 23, 1294-1300
85. VAN SCHILFGAARDE, R., VAN DER BURG, M.P., VAN SUYLICHEM, P.T. FROLICH, M. GOOSZEN, H.G.&MOOLENAAR, A.J. (1987) Interference by cyclosporine with the endocrine function of the canine pancreas. Transplantation 44, 13-16
86. VENKATAKRISHNAN, K., VON MOLTKE, L.L.&GREENBLATT, D.J. (2000) Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clinical Pharmacokinetics 38, 111-180
87. WATKINS, P.B. (1990) The role of cytochromes P-450 in cyclosporine metabolism. Journal of the American Academy of Dermatology 23, 1301-1311
88. WHALEN, R.D., TATA, P.N., BURCKART, G.J.&VENKATARAMANAN, R. (1999) Species differences in the hepatic and intestinal metabolism of cyclosporine. Xenobiotica 29, 3-9
89. WHEELER, D.J., ROBINS, A., PRITCHARD, D.I., BUNDICK, R.V. & SHAKIB, F. (1995) Potentiation of in vitro synthesis of human IgE by cyclosporin A (CsA). Clinical and Experimental Immunology 102, 85-90
90. WILLIAMS, M.D., WALSHAW, R., BULL, R.W., SCHALL, W.D., PADGETT, G.A., GOSSAIN, V.V.&NACHREINER, R.F. (1983) Effects of cyclosporine on allotransplanted pancreatic islets in DLE-MLC compatible dogs. Transplantation Procedings 4 (Suppl 1), 3004-3010
91. WONG, R.L., WINSLOW, C.M.&COOPER, K.D. (1993) The mechanisms of action of cyclosporin A in the treatment of psoriasis. Immunology Today 14, 69-74
92. ZACHARIAE, H. (1996) Long-term use of cyclosporine in dermatology. Archives of Dermatology 132, 692-694